Delayed Presentation of Drug-Induced Hepatic Injury

Shohana Ahmed ¹, Nirmal K. Onteddu ², Ali Jabur ¹, Sai Swarupa R. Vulasala ³, Swapna Kolli ⁴

1. Internal Medicine, Texas Tech University Health Sciences Center at Permian Basin, Odessa, USA 2. Internal Medicine/Hospitalist, Flowers Hospital, Dothan, USA 3. Medicine, Sri Venkateswara Medical College, Tirupati, IND 4. Internal Medicine, Texas Tech University Health Sciences Center at the Permian Basin, Odessa, USA

Corresponding author: Shohana Ahmed, shohana.ahmed@yahoo.com

Abstract

Drug-induced hepatotoxicity is a major cause of acute liver failure (ALF) in the United States. There are many offending agents like prescription drugs and herbal remedies. However, the most common prescription medication involved worldwide is amoxicillin-clavulanate. We report an unusually delayed presentation of severe cholestatic hepatitis caused by amoxicillin-clavulanate in a 20-year-old female with worsening hyperbilirubinemia that was successfully treated with corticosteroids and ursodeoxycholic acid (UDCA).

Categories: Family/General Practice, Internal Medicine, Gastroenterology

Keywords: drug-induced liver disease, amoxicillin – clavulanate, udca therapy

Introduction

With an incidence of 10 cases per 100,000 persons, drug-induced hepatotoxicity is a major cause of acute liver failure (ALF) in the United States [1-3]. There are many offending agents like prescription drugs and herbal remedies [4]. However, the most common prescription medication involved worldwide is amoxicillin-clavulanate [2, 5]. The liver injury associated with amoxicillin-clavulanate usually manifests within an average of three to four weeks from initial ingestion [5-6]. While the exact pathophysiology is still unknown, the presence of eosinophilic infiltrates indicates that the cholestatic-type injury caused by the antibiotic may be attributed to immunological factors [5, 7]. Withdrawal of the offending agent is usually the optimal management, however, corticosteroid therapy has been used in cases with severe cholestatic injury [5]. The common risk factors include advanced age, male sex, ethanol intake, medical illness, as well as combination of other hepatotoxic drugs [4, 8-11].

Case Presentation

A 20-year-old female patient with no significant past medical history presented to our hospital with a five-day history of nausea, vomiting, epigastric pain, and yellowing of the skin. She denied exposure to any recent medications, herbal supplements, illicit drugs, and alcohol. Vitals were within normal limits except for sinus tachycardia. Pertinent physical exam findings were conjunctival icterus, epigastric tenderness, with no associated splenomegaly or hepatomegaly. Significant laboratory workup revealed leucocytes of $13.5 \times 10^3/\text{mcl}$, hemoglobin 13.8 g/dL, platelet count $250 \times 10^3/\text{mcl}$, prothrombin time 13.6 s, INR 1.04, albumin 3.6 g/dL, serum glutamic-oxaloacetic transaminase (SGOT) 39 U/L, serum glutamic pyruvic transaminase (SGPT) 57 U/L, alkaline phosphatase 207 U/L, total bilirubin 6.9 mg/dL, lipase 50 U/L, amylase 93 U/L, gamma glutamyl transpeptidase 141 U/L, ferritin 232 ng/mL, and ceruloplasmin 51 mg/dL. Serologies for acute hepatotropic viruses, Herpes simplex virus, Epstein-Barr virus, autoimmune markers such as antinuclear antibody (ANA), antimitochondrial antibodies (AMA), antineutrophil cytoplasmic antibody (ANCA) were negative. All other laboratory results including hematological, biochemical, and metabolic panels were within normal limits.

Diagnostic imaging for the patient included an ultrasound of the abdomen and CT of abdomen and pelvis which showed a contracted and dilated gallbladder to 6 mm (Figure 1). Magnetic resonance cholangiopancreatography (MRCP) was negative for any extra- or intra-hepatic biliary obstruction so a liver biopsy was subsequently obtained (Figure 2). Histopathological examination revealed dense portal infiltrates dominated by neutrophils in the periductal region, but some within bile duct lumens. Substantial numbers of eosinophils accompanied the process in the periductal region. Figures 3-7 showed a prominent acute cholangitis composed of predominantly neutrophils. However, the biopsy was also remarkable for an increased number of accompanying eosinophils. This inflammatory infiltrate occupied Zone 1 and Zone 3 with relative sparing of the hepatic lobules, although there was a small amount of interface hepatitis likely contributing to the patient's elevated liver function tests (LFTs). The hepatic lobules were remarkable for moderate cholestasis. Overall hepatic lobules architecture was preserved, and there was no appreciable background steatosis or fibrosis. There was no evidence of autoimmune hepatitis as pathological and serological examinations were negative. There was no evidence of viral cytopathic effect. Reticulin and trichrome stains were unremarkable. Periodic acid Schiff-hematoxylin (PAS-H) and periodic acid Schiff-diastase stain (PAS-D) did not highlight any discrete intracytoplasmic globules. Iron was inconspicuous with

Received 07/08/2020
Review began 07/20/2020
Review ended 07/27/2020
Published 08/13/2020

© Copyright 2020

Ahmed et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

How to cite this article

Ahmed S, Onteddu N K, Jabur A, et al. (August 13, 2020) Delayed Presentation of Drug-Induced Hepatic Injury. Cureus 12(8): e9713. DOI 10.7759/cureus.9713

the iron stain.

FIGURE 1: CT abdomen and pelvis showing contracted gall bladder.

FIGURE 2: MRCP showing patent common bile duct (black arrow) and pancreatic duct (red arrow).

MRCP, magnetic resonance cholangiopancreatography

FIGURE 3: Inflammation of Zone 1 and Zone 3.

FIGURE 4: Acute lobular inflammation.

FIGURE 5: Mixed portal inflammation with eosinophils.

FIGURE 6: Portal mixed inflammation with eosinophils.

FIGURE 7: H&E cholestasis.

H&E, hemotoxylin and eosin

The histology from the liver biopsy was most consistent with acute large duct obstruction complicated by ascending cholangitis or drug-induced cholestatic hepatitis. However, imaging studies showed no evidence of calcified stones and no ductal dilation, which led to medication, illicit drug, and toxin involvement becoming the leading differential diagnosis. Upon further investigation of the patient's home medication list and a more thorough medication reconciliation a prescription for amoxicillin-clavulanate was found. The patient was treated approximately four months prior to admission for sinusitis with amoxicillin-clavulanate 825 mg/125 mg every 12 hours for 10 days. A corroborating history of present illness, this newly discovered antibiotic subscription, blood test, and biopsy results supported the probable diagnosis of drug-induced cholestatic hepatitis.

The patient was started on prednisone 40 mg daily and ursodiol 300 mg TID (four months after the last dose of amoxicillin-clavulanate was ingested). Following the commencement of treatment, improvement in clinical status and laboratory studies was seen. The patient was discharged and followed up as an outpatient with serial weekly labs.

Discussion

In 1984, amoxicillin-clavulanate was commercialized for the first time. The first-ever reported case of toxic hepatitis related to this antibiotic was from The Netherlands in 1988 [5, 12]. Amoxicillin-clavulanate is generally a well-tolerated antibiotic used for mild to moderate respiratory and cutaneous bacterial infections [12]. Amoxicillin as a single agent is rarely known to cause liver disturbances, however, it was suggested that the addition of clavulanic acid with amoxicillin may possibly be responsible for the adverse reaction [4].

The onset of the symptoms appears soon after completion of the therapy, typically appearing between 4 and 10 weeks after treatment [4, 9-10, 12]. Presenting symptoms include nausea, vomiting, fatigue, generalized malaise, jaundice, pruritus, decreased appetite, dark urine, and light-colored stool suggestive of cholestatic pattern. Other less commonly reported symptoms are the appearance of skin rash and fever. Abdominal examination may show painful hepatomegaly which is also less common.

While the exact pathophysiology of amoxicillin-clavulanate induced hepatotoxicity is still unknown -- eosinophilic infiltrates, skin rash, hypereosinophilia, and positive diagnostic autoantibodies (mitochondrial type 6, anti LKM2, and anti LM antibodies) reinforce the hypothesis of immunoallergic mechanisms caused by the drug [5, 12].

The pattern of amoxicillin-clavulanate associated hepatic damage is predominantly cholestatic, but patients

can also present with hepatocellular or mixed cholestatic/hepatocellular patterns. Liver biopsy findings include centrilobular or pan lobular cholestasis with predominant lymphocytic infiltration along with neutrophils and eosinophils. Cholestasis mainly involves portal and periportal areas [4-5]. Ductopenia, necrosis and degeneration of ductal epithelial cells, and vacuolization and necrosis of liver cells are some other findings besides the granulomatous inflammatory process [5, 13-15].

Drug-induced liver injury (DILI) frequently causes diagnostic dilemmas and is often overlooked in medical practice. Diagnosis of DILI includes multifaceted approaches such as establishing a causal relationship between the pharmacotherapy and onset of clinical manifestations, obtaining a detailed pharmacological history, excluding other causes of hepatotoxicity, biochemical profiles, and histological findings.

No targeted treatment for amoxicillin-clavulanate induced hepatic damage is available apart from symptomatic management. Early recognition and prompt cessation of offending agents can prevent further injury [9]. Few studies have indicated that ursodeoxycholic acid (UDCA) arrested drug-induced cholestasis in two-third of cases [16].

Some authors also advocated the use of steroid treatment in patients with high bilirubin levels, LFT abnormalities, and neurological impairment [17]. Their efficacy is yet to be determined in a randomized controlled trial setting [18].

Our patient manifested with nausea, vomiting, epigastric pain, and yellowish discoloration of skin four months after her last dose of amoxicillin-clavulanate. Her bilirubin, alkaline phosphatase, and transaminase levels continued to rise with no improvement in clinical symptoms. Other causes of liver injury including obstructive jaundice were ruled out. Based on the Council for International Organizations of Medical sciences Score (CIOMS) of +8 points (suggestive of very likely association), The Clinical Diagnostic Scale (CDS) of +11 points (suggestive of possible association), Adverse Drug Reaction Probability (Naranjo) score of +6 points (suggestive of probable association) along with the presence of dense portal infiltrate dominated by neutrophils, eosinophils in the periductal region- our patient had a high probability of DILI.

The patient did not have any improvement in her clinical symptoms during the observation period. She also developed progressive worsening of cholestasis. The patient was started on a tapering dose of prednisone 40 mg daily and UDCA 300 mg three times a day. The therapy resulted in quick resolution of symptoms as well as jaundice.

The exact mechanism of steroid therapy remains enigmatic. Nevertheless, the close association between initiation of steroid therapy and improvement in LFTs implies that corticosteroid may be a plausible salutary option for some patients with DILI. As of this publication only a few cases of drug-related cholestatic hepatitis managed successfully with steroids have been reported [5, 17, 19-20]. A pertinent factor which led to a diagnostic dilemma in this case was the patient's denial of using any prescription drug or medication in recent past. This case also emphasized the need for thorough medication reconciliation upon admission to the acute care setting to avoid diagnostic delays and dilemmas especially in patient with drug induced causes.

Conclusions

In conclusion, the amoxicillin-clavulanic acid combination may cause delayed cholestatic hepatitis. Though the mechanism is not clear as of yet, it is suggested to be an immune-allergenic or an idiosyncratic reaction. The symptoms could appear weeks after the discontinuation of the medication, however, it is reassuring that the clinical course is benign with a good prognosis.

Additional Information

Disclosures

Human subjects: Consent was obtained by all participants in this study. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Agarwal VK, McHutchison JG, Hoofnagle JH, Drug-Induced Liver Injury Network: Important elements for the diagnosis of drug-induced liver injury. *Clin Gastroenterol Hepatol*. 2010, 8:463-470. [10.1016/j.cgh.2010.02.008](https://doi.org/10.1016/j.cgh.2010.02.008)
2. Laster J, Satoskar R: Aspirin-induced acute liver injury. *ACG Case Rep J*. 2014, 2:48-49. [10.14309/crj.2014.81](https://doi.org/10.14309/crj.2014.81)
3. Bell LN, Chalasani N: Epidemiology of idiosyncratic drug-induced liver injury. *Semin Liver Dis*. 2009, 29:337-347. [10.1055/s-0029-1240002](https://doi.org/10.1055/s-0029-1240002)

4. Dandakis D, Petrogiannopoulos C, Hartzoulakis G, et al.: Cholestatic hepatitis associated with amoxycillin--clavulanic acid combination. A case report. *Ann Gastroenterol Hepatol*. 2002, 15:85-87.
5. Herrero-Herrero J-I, García-Aparicio J: Corticosteroid therapy in a case of severe cholestatic hepatitis associated with amoxicillin-clavulanate. *J Med Toxicol*. 2010, 6:420-423. [10.1007/s13181-010-0019-4](#)
6. Andrade RJ, Lucena MI, Fernández MC, et al.: Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. *Gastroenterology*. 2005, 129:512-521. [10.1016/j.gastro.2005.05.006](#)
7. Gresser U: Amoxicillin-clavulanic acid therapy may be associated with severe side effects -- review of the literature. *Eur J Med Res*. 2001, 6:139-149.
8. Rodríguez LAG, Stricker BH, Zimmerman HJ: Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid. *Arch Intern Med*. 1996, 156:1327-1332.
9. Reddy KR, Brillant P, Schiff ER: Amoxicillin-clavulanate potassium-associated cholestasis. *Gastroenterology*. 1989, 96:1135-1141. [10.1016/0016-5085\(89\)91633-8](#)
10. Larrey D, Vial T, Micaleff A, et al.: Hepatitis associated with amoxycillin-clavulanic acid combination report of 15 cases. *Gut*. 1992, 33:368-371. [10.1136/gut.33.3.368](#)
11. Mari JY, Guy C, Beyens MN, Ollagnier M: Delayed drug-induced hepatic injury. Evoking the role of amoxicillin-clavulanic acid combination. *Thérapie*. 2000, 55:699-704.
12. Beraldo DO, Melo JF, Bonfim AV, Teixeira AA, Teixeira RA, Duarte AL: Acute cholestatic hepatitis caused by amoxicillin/clavulanate. *World J Gastroenterol*. 2013, 19:8789-8792. [10.3748/wjg.v19.i46.8789](#)
13. Kim JS, Jang YR, Lee JW, et al.: A case of amoxicillin-induced hepatocellular liver injury with bile-duct damage. *Korean J Hepatol*. 2011, 17:229-232. [10.3350/kjhep.2011.17.3.229](#)
14. Farrokhseresht R: Liver associated injury of amoxicillin-clavulanic acid . *SEMJ*. 2001, 2:53-56.
15. Silvain C, Fort E, Levillain P, Labat-Labourdette J, Beauchant M: Granulomatous hepatitis due to combination of amoxicillin and clavulanic acid. *Dig Dis Sci*. 1992, 37:150-152. [10.1007/BF01308359](#)
16. Velayudham LS, Farrell GC: Drug-induced cholestasis. *Expert Opin Drug Saf*. 2003, 2:287-304. [10.1517/14740338.2.3.287](#)
17. Giannattasio A, D'Ambrosi M, Volpicelli M, Iorio R: Steroid therapy for a case of severe drug-induced cholestasis. *Ann Pharmacother*. 2006, 40:1196-1199. [10.1345/aph.1G345](#)
18. Lee WM: Drug-induced hepatotoxicity. *N Engl J Med*. 2003, 349:474-485. [10.1056/NEJMra021844](#)
19. Alberti L, Alberti-Flor JJ: Ticlopidine-induced cholestatic hepatitis successfully treated with corticosteroids . *Am J Gastroenterol*. 2002, 97:1072.
20. Giordano N, Nardi P, Santacroce C, Geraci S, Gennari C: Acute hepatitis induced by cyproterone acetate . *Ann Pharmacother*. 2001, 35:1053-1055. [10.1177/106002800103500902](#)